Xconomy: Amgen News, Articles and Opinions

“amgen” Archives

Entry	Author	Date	Location
Bio Roundup: Zolgensma Watch, Brain Cancer Blues, Peloton Payout & More	Alex Lash	05/24/19	National
MedCo Touts New Data for Long-Lasting Heart Drug as Reckoning Looms	Ben Fidler	05/20/19	New York
ASCO Abstracts: Breast Cancer, Precision Treatments in the Spotlight	Ben Fidler	05/16/19	National
SMA, Migraine Data Lead Neuro Highlights from AAN Meeting	Ben Fidler	05/07/19	National
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments	Frank Vinluan	05/03/19	National
Teva’s Approved Migraine Drug Fails Again to Blunt Rarer Headache	Frank Vinluan	04/23/19	New York
Bio Roundup: Nationwide’s Rise, a Surgeon’s Quest, CRISPR USA & More	Ben Fidler	04/19/19	National
Bio Roundup: Gottlieb’s Goodbye, AACR Recap, Migraine Drug Fight & More	Frank Vinluan	04/05/19	National
Bio Roundup: Pharma in DC, Bristol-Cel in Trouble, Roche Gets A Spark	Ben Fidler	03/01/19	National
Losing “Scalps”? Despite Pharma Fear, A Split on Trump Rx-Price Plans	Ben Fidler	02/12/19	National
AbbVie Joins Myeloma Race with $90M Deal for Rights to Teneobio Drug	Frank Vinluan	02/11/19	San Francisco
Matching Amgen, Regeneron to Cut List Price of Heart Drug by 60%	Ben Fidler	02/11/19	New York
Bio Roundup: Aimmune Drama, Shutdown Blues, Perlmutter Talks Cancer	Ben Fidler	01/18/19	National
FDA Panel Backs Amgen Bone Drug, Says Benefits Outweigh Heart Risks	Frank Vinluan	01/16/19	National
Merck And The Future of Immuno-Oncology: A Chat With Roger Perlmutter	Ben Fidler	01/16/19	National
Bio Roundup: #JPM19 Notes, Loxo Buyout, Black Diamond’s Cash & More	Frank Vinluan	01/11/19	National
From Alnylam to Zayner: Xconomy’s Top Innovation Stories of 2018	Gregory T. Huang	12/27/18	National
15 For ’19: Key Clinical Data to Watch For Next Year (Part 2)	Ben Fidler	12/18/18	National
15 for ’19: Key Clinical Data to Watch for Next Year (Part 1)	Ben Fidler	12/17/18	National
Moderna Raises $604M and Nails Down Biotech’s Biggest IPO Ever	Ben Fidler	12/06/18	Boston
BCMA Day: At ASH ‘18, Cell Therapies For Myeloma Take Center Stage	Ben Fidler	12/04/18	National
ASH 2018: A Guide to the Latest for Blood-Borne Cancers and More	Alex Lash	11/26/18	National
Eyeing $500M, Moderna Outlines Plans for Biotech’s Biggest IPO Ever	Ben Fidler	11/09/18	Boston
Bio Roundup: Midterm Fallout, Alzheimer’s Search, Postpartum Panel	Ben Fidler	11/09/18	National
Amgen Picks Provention to Continue Development of Celiac Disease Drug	Frank Vinluan	11/05/18	New York
89Bio Joins NASH Chase with a Teva Drug and $60M in Funding	Frank Vinluan	10/25/18	San Francisco
Amgen Slashes Cholesterol Drug Price 60% to Match Rival Regeneron	Frank Vinluan	10/24/18	National
Bio Roundup: Prices on TV, Novartis Hearts Radio, Warp Drive’s End	Ben Fidler	10/19/18	National
Report: Express Scripts Shuts Out Teva Migraine Drug, Prefers Rivals	Frank Vinluan	10/17/18	National
Bio Roundup: Nobel Prizes, Duchenne Steps, Guardant’s IPO & More	Frank Vinluan	10/05/18	National
Page 1 of 20	next page »